David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings... Follow @motleydavid
- Feb 7, 2014 at 6:30PM
- Health Care
- Can UnitedHealth Group and Johnson & Johnson Continue Their Winning Ways?
- Here's Why Aphria Is the Next Marijuana Stock to List on the NYSE
- Up 314% in One Day ... and Then Another 58%: How to Find the Next Amarin
- Better Buy: GlaxoSmithKline plc vs. Eli Lilly
- Why Endocyte, Inc. Stock Is Soaring Today